09Oct 2023
Sun Pharma and Aurobindo Pharma Initiate Drug Recalls in US Market Over Manufacturing Issues

Sun Pharma and Aurobindo Pharma Initiate Drug Recalls in US Market Over Manufacturing Issues

Sun Pharma and Aurobindo Pharma are conducting recalls of drugs from the US market due to manufacturing issues, as confirmed by the US Food & Drug Administration (FDA). Sun Pharma's US subsidiary is recalling 69,707 cartons of Cequa, a medication for dry eyes, citing subpotency concerns. Aurobindo Pharma is recalling 9,890 bottles of Rasagiline Tablets for Parkinson's disease treatment due to failed dissolution specifications. As per the FDA, these recalls fall under the Class III and Class II categories, indicating minimal to temporary health risks.

  • #family health

Like

Save

Share